Wisconsin-based Promega has earned a CE mark for its OncoMate MSI Dx analysis system for detecting microsatellite instability (MSI) in solid tumors.

MSI biomarkers can be used to predict a patient’s response to immune-oncology therapies for certain cancers.

“Screening cancer patients with these reliable markers” can help guide care and treatment decisions, the company said.